La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Neumora Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Neumora Therapeutics..

Neumora Therapeutics (NASDAQ:NMRA) Azioni, Catena delle Opzioni

Neumora Therapeutics

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics Inc

Truist Securities analyst Michael Roxland maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Hold and lowers the price target from $76 to $71.

News

Price Target

Analyst Ratings

BERY

Truist Securities Maintains Hold on Berry Global Gr, Lowers Price Target to $71

Truist Securities analyst Michael Roxland maintains Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) with a Buy and lowers the price target from $65 to $58.

BALL

Truist Securities Maintains Buy on Ball, Lowers Price Target to $58

<a href="https://www.bloomberg.com/news/articles/2025-04-22/apple-s-new-siri-chief-mike-rockwell-overhauls-management-to-start-turnaround" title="https://www.bloomberg.com/news/articles/2025-04-22/apple-s-new-siri-chief-mike-rockwell-overhauls-management-to-start-turnaround">https://www.bloomberg.com/news/articles/2025-04-22/apple-s-new-siri-chief-mike-rockwell-overhauls-management-to-start-turnaround</a>

Management

AAPL

'Apple's New Siri Chief Enlists Vision Pro Talent to Start Comeback Bid' - Bloomberg News

Truist Securities analyst Michael Roxland maintains Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Buy and lowers the price target from $215 to $210.

Truist Securities Maintains Buy on Avery Dennison, Lowers Price Target to $210

Barclays analyst Jared Shaw maintains Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) with a Underweight and raises the price target from $64 to $67.

Barclays Maintains Underweight on Bank of Hawaii, Raises Price Target to $67

Truist Securities analyst Brian Foran maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Buy and lowers the price target from $340 to $315.

Truist Securities Maintains Buy on American Express, Lowers Price Target to $315

There's weed and then there are pre-rolls.
And in 2025, the pre-roll isn't some stoner afterthought; it's the front-runner. In California, it's a cultural statement. In Canada, it's a quietly dominant force. Same format, different vibe. One market moves fast and loud; the other, slow and surgical. But both are being reshaped by the same force: the rise of the ready-made joint.
<h2 class="wp-block-heading">California: Where Pre-Rolls Come With Swagger</h2>
Let's start with the loudest room in the house.
Between December 2024 and February 2025, Californians bought $178.1 million worth of pre-rolls—16.1% of all cannabis sales in the state, per RollPros and BDSA. And most of those joints? They came supercharged. Infused products now make up 66.3% of all pre-roll sales.
The king of this hill? Jeeter. $26.7 million in sales this quarter. 15% of the market. Right behind them: STIIIZY's "40s" series of 0.5g five-packs, which alone account for 22% of California's entire pre-roll market.
This isn't a niche anymore—it's the standard.
And it's not just about grams and dollars. In this <a href="https://www.forbes.com/sites/willyakowicz/2025/04/18/inside-stiiizy-the-worlds-best-selling-weed-brand/">Forbes cover story,</a> Will Yakowicz dives into what makes STIIIZY tick. CEO James Kim says it plainly: "I just know the consumer. That's the missing piece from the corporate guys—they don&#8217;t know the consumer." That might explain how his company, born in the gray market haze of 2017, now pulls in over $800 million annually and sits at the top of a cannabis empire with nearly 50 branded stores.
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/04/44818968/how-one-european-company-is-flooding-america-with-cannabis-seeds">How One European Company Is Flooding America With Cannabis Seeds</a>
It's not all clean and polished. There have been rumors, lawsuits, scrutiny. But that rough edge? For many in the legacy market, it adds credibility. STIIIZY didn't come from Whole Foods—it came from DTLA. And the market rewards that.
<h2 class="wp-block-heading">Canada: Slower, Calmer, Just As Deep</h2>
Up north, pre-rolls are a quieter success story. In some provinces, they account for up to 40% of legal sales. Nationally? 32%, according to the latest from <a class="" href="http://www.zuanicassociates.com/">Zuanic &amp; Associates</a>, citing Hifyre data.
Here, too, infused is rising—but at a more measured pace. After years of double-digit growth, the segment has plateaued at around 34% of pre-roll sales. That's still huge.
Top players? Decibel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTC">DBCCF</a>) leads with 26% of the infused joint market, but it's losing steam. Rising fast are BZAM (with Jeeter), Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) —via Claybourne— and OGI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>)/Motif. Unlike California, pricing in Canada has stayed mostly stable. In fact, most brands that gained share raised prices year over year. A flex if there ever was one.
Where Canada lags? Format. Multipacks are still catching on. In California, they're the gold standard. In Canada, they're just starting to matter—and that's a gap ripe for disruption.
<h2 class="wp-block-heading">So What's The Play?</h2>
Same product, two different speeds.
California moves like a streetwear drop. Fast, brand-driven, fueled by flavor and hype. Canada leans clinical—steady, data-minded, focused on consistency and structure.
But consumers in both markets are pointing the way. Potency matters. Convenience matters. Innovation matters. And pre-rolls are no longer the bonus item; they're the main event.
Analyst Pablo Zuanic frames it like this: "Pre-rolls continue to outgrow the Canadian rec market and over-index versus the U.S." And in California? The numbers speak for themselves.
Jeeter. STIIIZY. Claybourne. Boxhot. These brands aren't just selling cannabis. They're selling identity, repeatability and a new kind of ritual.
<h2 class="wp-block-heading">The Bigger Picture</h2>
For investors and operators, this isn't just fluff &#8211; it's strategy. Infused pre-rolls are one of the few high-margin formats that still enjoy consistent consumer demand. The California model is spreading, one licensing deal at a time. Canadian producers have proof that pricing power still exists—if the product delivers.
And if you're still treating pre-rolls like an add-on? You're missing the moment.
Photo: Shutterstock

Cannabis

DBCCF

Why Pre-Rolls Are Cannabis' Most Profitable Format, From California To Canada

Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) has outperformed the market over the past 5 years by 5.86% on an annualized basis producing an average annual return of 18.76%. Currently, Corteva has a market capitalization of $40.38 billion. 
Buying $1000 In CTVA: If an investor had bought $1000 of CTVA stock 5 years ago, it would be worth $2,298.06 today based on a price of $59.12 for CTVA at the time of writing.
<h3>Corteva's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745338511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CTVA

Here's How Much $1000 Invested In Corteva 5 Years Ago Would Be Worth Today

Truist Securities analyst Michael Roxland maintains Amcor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) with a Buy and lowers the price target from $12 to $11.

AMCR

Truist Securities Maintains Buy on Amcor, Lowers Price Target to $11

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and raises the price target from $72 to $73.

Barclays Maintains Overweight on Xcel Energy, Raises Price Target to $73

Truist Securities analyst David Smith maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and lowers the price target from $45 to $41.

ALLY

Truist Securities Maintains Buy on Ally Financial, Lowers Price Target to $41

Barclays analyst Nicholas Campanella maintains Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Equal-Weight and raises the price target from $83 to $90.

Barclays Maintains Equal-Weight on Southern, Raises Price Target to $90

Piper Sandler analyst Harsh Kumar maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Overweight and lowers the price target from $140 to $100.

Piper Sandler Maintains Overweight on Impinj, Lowers Price Target to $100

Piper Sandler analyst David Westenberg maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and lowers the price target from $6.4 to $5.

NEOG

Piper Sandler Maintains Neutral on Neogen, Lowers Price Target to $5

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and raises the price target from $47 to $48.

Barclays Maintains Equal-Weight on Portland Gen Electric, Raises Price Target to $48

<a href="https://www.bloomberg.com/news/articles/2025-04-22/bessent-sees-de-escalation-with-china-situation-unsustainable">https://www.bloomberg.com/news/articles/2025-04-22/bessent-sees-de-escalation-with-china-situation-unsustainable</a>

Macro Economic Events

Politics

Economics

General

'Bessent Sees De-Escalation With China, Situation Unsustainable'- Bloomberg

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/04/2025-04-22_08h44_46.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Safe Havens</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-gold-3500-high-safe-havens-gld-mc-04222025">click here</a> for an enlarged chart of gold ETF SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).
Note the following:
<ul>
<li>The weekly chart shows the longer term big picture of the safe haven gold.</li>
<li>The chart shows gold has gone parabolic.&nbsp; Gold hit a record $3500 before pulling back.</li>
<li>Gold and Japanese yen are considered safe havens.  Money is rushing into these safe havens.  Yen hit the psychologically important level of 140. As full disclosure, there are positions in gold ETF (GLD) and yen ETF Invesco Currency Shares Japanese Yen Trust (FXY) in our ZYX Allocation Model Portfolios.</li>
<li>Money is flowing into safe havens as foreign investors lose faith in the U.S. dollar.  The dollar has been the reserve currency of the world, which is one of the reasons for the nation&#8217;s prosperity.  It has allowed the U.S. to borrow and spend recklessly.  The national debt stands at $36.7T, not including unfunded liabilities.  Including unfunded liabilities such as social security and Medicare, the debt stands at over $1.34 million for every household in the U.S.</li>
<li>Right now, the stock market is a prisoner of news on trade talks.  In our analysis, stock market bulls are overly optimistic in their assertion that trade agreements will be reached very quickly.  In our analysis, it is going to be a mixture of progress and delays.</li>
<li>In our analysis, the stock market can significantly rally on trade deals. </li>
<li>From this morning, there are two great examples illustrating the foregoing point.
<ul>
<li>&nbsp;Thailand Prime Minister Paetongtarn Shinawatra announced trade talks with Thailand, originally scheduled for April 23, have been delayed.&nbsp; A set of issues remains to be resolved.</li>
<li>Stock futures are reversing to buying in the early trade on positive news of "significant progress" in India trade talks.&nbsp; Vice President JD Vance met with India Prime Minister Narendra Modi. &nbsp; Vance said, "We believe a stronger India means greater economic prosperity, but also greater stability across the Indo- Pacific, which is, of course, a shared goal for all of us.</li>
</ul>
</li>
<li>In addition to studying ways to fire Fed Chair Powell, there are signals from the White House that President Trump is planning to undercut the Federal Reserve, bringing its legitimacy into question, if Powell does not cut interest rates.&nbsp; The Fed rate decision will be announced on May 7.&nbsp;&nbsp;</li>
<li>A flurry of Fed speak is ahead today that may provide investors with insights. &nbsp; Vice Chair Philip Jefferson is speaking at 9am ET.&nbsp; Philadelphia Fed President Patrick Harker is speaking at 9:30am ET.&nbsp; Minneapolis Fed President Neel Kashkari is speaking at 1:40pm ET.&nbsp; Richmond Fed President Tom Barkin is speaking at 2:30pm ET.&nbsp; Governor Adriana Kugler is speaking at 6pm ET.</li>
<li>Adding to the positive sentiment this morning is that Amazon.com, Inc. (AMZN) has debunked a rumor that hurt NVIDIA Corp (NVDA), Advanced Micro Devices, Inc. (AMD), Micron Technology Inc (MU), Broadcom Inc (AVGO), Marvell Technology Inc (MRVL), and other AI stocks yesterday.  The rumor was that Amazon was pulling back on AI infrastructure.  Amazon has denied the rumor.  </li>
<li>Tesla Inc (TSLA) earnings are ahead after the regular session close.  Due to the popularity of TSLA stock with retail investors, moves in TSLA stock impact stock market sentiment.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in AMZN, NVDA, TSLA, Microsoft Corp (MSFT), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), and Apple Inc (AAPL).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing buying.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Arora Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Earnings

Equities

Market Summary

Broad U.S. Equity ETFs

Commodities

Forex

Global

Opinion

Federal Reserve

Markets

$BTC

Amazon Debunks Rumor That Hurt Nvidia; Gold Hits $3500, Yen Hits 140; Stocks Bounce On India Talks

Quest Diagnostics Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.63 billion</a>.
The diagnostic test provider reported quarterly adjusted earnings of $2.21 per share, up 8.3%, <a href="https://www.benzinga.com/pressreleases/25/04/n44917998/quest-diagnostics-reports-first-quarter-2025-financial-results-reaffirms-revenue-and-adjusted-dilu" target="_blank" rel="noreferrer noopener">beating the consensus of $2.15</a>.
&#8220;In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access,&#8221; said Jim Davis, chairman, CEO and president. &#8220;We are reaffirming our revenue and adjusted EPS guidance for the full year 2025.&#8221; 
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44921124/ge-aerospace-expands-q1-operating-margins-ceo-talks-cost-control-to-mitigate-tariff-impact" rel="noreferrer noopener">GE Aerospace Expands Q1 Operating Margins, CEO Talks Cost Control To Mitigate Tariff Impact</a>
Revenue per requisition increased by 0.3%, requisition volume increased 12.4% and organic requisition volume fell slightly by 0.9%.
Adjusted Operating income increased 16.3% to $406 million, while margin improved from 14.8% to 15.3%.
Outlook: Quest Diagnostics reaffirms 2025 guidance for <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43346695/quest-diagnostics-delivers-q4-earnings-beat-the-details" rel="noreferrer noopener">revenue of $10.70 billion—$10.85 billion</a> versus the consensus of $10.78 billion and adjusted EPS of $9.55-$9.80 compared to the consensus of $9.68.
In February, Quest agreed to acquire select assets of Fresenius Medical Care AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) wholly owned Spectra Laboratories. Financial terms were not disclosed. The acquisition is expected to close in the second half of 2025. The transition of services is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43910114/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics" rel="noreferrer noopener">complete by early 2026</a>.
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the U.S.
In February, GRAIL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) and Quest Diagnostics announced the initial phase of a program to improve provider access to GRAIL&#8217;s Galleri multi-cancer early detection test.
Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system that enables providers in the U.S. to order and receive reports of laboratory tests electronically through Quest&#8217;s Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity <a href="https://www.benzinga.com/pressreleases/25/02/n43657458/grail-and-quest-diagnostics-provide-grails-galleri-multi-cancer-early-detection-mced-test-through-" target="_blank" rel="noreferrer noopener">system last year</a>.
William Blair writes, &#8220;At first glance, these results are in line with what we would expect from Quest — consistent and with little drama.&#8221;
&#8220;We remain comfortable with the 2025 guide, as Quest continues to benefit from prudent utilization assumptions, mix benefits, flattish unit pricing, a more favorable regulatory environment and plenty of acquisition targets,&#8221; analyst Andrew Brackmann noted.
The William Blair analyst added, &#8220;Beyond the favorable industry backdrop, we believe Quest should be well insulated from macroeconomic noise, with the overwhelming majority of revenue coming from the U.S. and what we think will be minimal (likely offset) impact from tariffs.&#8221; The analyst reiterated the Outperform rating.
DGX Price Action: Quest Diagnostics stock is up 7.83% to $174.53 at publication on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure" target="_blank" rel="noreferrer noopener">3M Stock Surges After Q1 Beat As 2025 Outlook Flags Tariff Pressure</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Large Cap

Guidance

Health Care

Reiteration

Movers

GRAL

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

Piper Sandler analyst Stephen Scouten maintains Servisfirst Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NYSE">SFBS</a>) with a Neutral and lowers the price target from $96 to $84.

SFBS

Piper Sandler Maintains Neutral on Servisfirst Bancshares, Lowers Price Target to $84

Barclays analyst Nicholas Campanella maintains OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Equal-Weight and raises the price target from $44 to $45.

Barclays Maintains Equal-Weight on OGE Energy, Raises Price Target to $45

Legal

Press Releases

Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA)

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit

Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA

NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit

NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA

Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

Penny Stocks

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA

Comments

Neumora Therapeutics

Neumora Therapeutics (NMRA) Opzioni

Neumora Therapeutics (NASDAQ:NMRA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO